Adcendo
Develops first- and best-in-class antibody-drug conjugates (ADCs) for cancer treatment
$75MSeries C
Role not disclosedLC
Logos Capital
Activity from announced rounds
Activity in this selectionthe-family-fund-075bdd15
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $325M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionMirador Therapeutics
Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases
$250MSeries B
Role not disclosed